CancerDrs

Liver Cancer clinical trials in District of Columbia

6 actively recruiting liver cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia:
  • Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in District of Columbia:
  • Johns Hopkins University, Sibley Memorial Hospital — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…

Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in District of Columbia:
  • Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
NA Recruiting Federal

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HC…

Sponsor: VA Office of Research and Development
NCT ID: NCT05486572
Sites in District of Columbia:
  • Washington DC VA Medical Center, Washington, DC — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surv…

Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
NCT ID: NCT02333604
Sites in District of Columbia:
  • Cancer Support Community Research & Training Institute — Washington D.C., District of Columbia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12